Investing in High-Potency Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Investing in High-Potency Manufacturing
Market demand for cytotoxic drugs is leading CMOs to expand their API manufacturing and formulation services.

Pharmaceutical Technology

Certification for high-potency manufacturing
Lonza (Basel, Switzerland) is investing CHF 80 million ($68 million) for a new manufacturing site in Visp, Switzerland, for large-scale production of highly potent APIs. As part of the investment, Lonza plans to hire approximately 40 new employees by 2009.

Lonza is also adding large-scale production of antibody drug conjugates. The manufacture of antibody drug conjugates involves the coupling of a highly active chemical substance with a biotechnologically manufactured antibody. Lonza is investing in a new production unit and supporting development and analytical laboratories, all to be located in Visp. Construction of the commercial-scale plant in Visp began in the last quarter of 2006. Stage I is expected to be on line in 2008. The plant will initially be capable of producing more than 100 kg of antibody drug conjugates per year, and future expansion plans are built into the design. Lonza currently operates laboratory-scale production of drug antibody conjugates and is bringing small-scale pilot facilities on stream in 2007.

Carbogen Amcis (Bubendorf, Switzerland), which offers manufacturing of highly potent APIs, added new high potency analytical and quality-control laboratories at is facilities in Bubendorf, Switzerland, earlier this year. The laboratories are designed to support analytics of highly potent compounds down to an occupational exposure limit of 0.3 μg/m3 .

Cambrex (East Rutheford, NJ) is adding laboratory space to its high potency site in Charles City, Iowa. The project adds 11,500 ft2 with five new process development and kilo-laboratory production suites for highly potent APIs. The expansion also includes enhanced facilities for analytical development and quality control. Cambrex expects the expansion to be completed in early 2008.

Aptuit (Greenwich, CT) gained high-potency manufacturing capabilities with the acquisition of EaglePicher Pharmaceutical Services. Aptuit completed its purchase of EaglePicher Pharmaceutical Services earlier this year.

NPIL Pharma (Mumbai, India) also recently expanded its high-potency substance facility in Grangemouth, Scotland. The Grangemouth facility provides contract manufacturing of cytotoxics and prostaglandins for preclinical and clinical development. The expansion includes the recruitment of 16 additional technical and operational employees and a roughly $500,000-investment in containment upgrades. The hardware investment brought more CGMP capacity for clinical trial materials on stream in late 2006. The new containment upgrades to an existing GMP suite include additional high-integrity barrier isolation for the safe handling for Category IV–V toxins for conjugation to monoclonal antibodies and targeting agents. NPIL Pharma gained the Grangemouth facility as part of its acquisition of the custom manufacturer Avecia Pharmaceuticals in December 2005.

Ferro Pfanstiehl Laboratories (Waukegan, IL) expanded its manufacturing capabilities for highly potent APIs last year. In 2006, the company commissioned a new Class IV (performance-based exposure control level) containment facility in Waukegan, Illinois. The facility is designed for low-volume production of highly potent APIs, including small-molecule new chemical entities in early-phase development. The 2000-ft2 addition offers production of preclinical through commercial quantities ranging from 1–5 kg. The kilo laboratory complements product batch capacities of 3–50 kg in Ferro Pfanstiehl's existing commercial containment facility in Waukegan.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here